We are committed to meeting the
needs of patients, providers, and the
We are committed to meeting the needs of patients, providers, and the healthcare marketplace
We value partnership, collaborating with pharmaceutical and biotech industry leaders as we strive to develop and deliver medicines to the oncology community.
MorphoSys and Incyte
MorphoSys has signed a global collaboration and licensing agreement with Incyte Corporation to further develop and commercialize MorphoSys’ proprietary anti-CD19 antibody tafasitamab.
Tafasitamab is an Fc-engineered antibody against CD19 currently in clinical development for the treatment of B-cell malignancies.
See who we’re partnered with at morphosys.com/partneringLearn About Our History